General Information of Drug (ID: DMHFBOG)

Drug Name
SAR231893 Drug Info
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 3 [1]
Atopic dermatitis EA80 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMHFBOG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dupilumab DMOAD2Y Atopic dermatitis EA80 Approved [2]
CBP-201 DMWYNN1 Atopic dermatitis EA80 Phase 3 [3]
Aerovant DMUB8WN Asthma CA23 Phase 2a [4]
SAR-156597 DMUICJD Idiopathic pulmonary fibrosis CB03.4 Phase 2 [5]
PRX-321 DM7YWVT Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
Altrakincept DMLSK01 Asthma CA23 Phase 2 [7]
AZD1402 DM73O6I Asthma CA23 Phase 2 [8]
AMG 317 DMUO3T2 Asthma CA23 Discontinued in Phase 1 [9]
PRS-060 DM8GCHX Asthma CA23 Investigative [5]
APG-201 DM0BVJN Solid tumour/cancer 2A00-2F9Z Investigative [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 4 receptor alpha (IL4R) TTDWHC3 IL4RA_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT02134028) Long-Term Safety Evaluation of Dupilumab in Patients With Asthma. U.S. National Institutes of Health.
2 Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66.
3 Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Ralpha, for the treatment of Th2 inflammatory diseases. Sci Rep. 2023 Jul 31;13(1):12411.
4 Aerovance starts trial of Aerovant for uncontrolled asthma. Aerovance. March 3, 2009.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1697).
6 Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring. J Pharmacol Exp Ther. 2009 Aug;330(2):520-5.
7 The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
8 Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma. J Allergy Clin Immunol. 2023 Apr;151(4):966-975.
9 Clinical pipeline report, company report or official report of Amgen (2009).